TCT 2021 Announces Late-Breaking Clinical Trials

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) meeting, sponsored by the Cardiovascular Research Foundation (CRF).

Due to COVID-19, the meeting will be condensed and only a limited number of attendees were being allowed to attend and they need to meet strict health safety requirements. The meeting will have both an in-person and virtual component. There is no expo floor at this year's meeting.  

November 9, 2021 — Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis, but a higher rate of access

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PE

November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further bloo

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 trial found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year adverse events compared to coronary artery

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in patients with diabetes mellitus (DM) and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to t

November 9, 2021 — New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery.

November 9, 2021 — An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk,

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure the severity of artery blockages can lead to significantly improved outcomes after percutaneous coronary intervention (PCI), according to a new study done in collaboration with Mount Sinai faculty.

November 20, 2021 – Philips announced it signed an agreement to acquire Cardiologs, a France-based medical technology company focused on cardiac diagnostics using artificial intelligence (AI) and cloud technology. Cardiologs will further strengthen Philips’ cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis and reporting services. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now